Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02661022 · MORE INFO

Limitations, agreements, and source contact

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma · Source last updated 2024-04-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Institution's individual results may be submitted for publication only after the results of the multicenter study are published, 18 months after study completion at all sites, or notification from Stemline Therapeutics, Inc. that submission of a multicenter publication is no longer planned, whichever shall occur first.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
This study was terminated early due to slow accrual and changes to Sponsor's development program priorities. The third dose level (12 µg/kg/day), for Phase 2, was not investigated.
point Of Contact
email
clinicaltrials@menarinistemline.com
organization
Stemline Therapeutics, Inc.
phone
877-332-7967
title
Ira Gupta, MD, Senior Vice President, Clinical Development & Medical Affairs - Hematology
Complete source fields
certain Agreement
other Details
Institution's individual results may be submitted for publication only after the results of the multicenter study are published, 18 months after study completion at all sites, or notification from Stemline Therapeutics, Inc. that submission of a multicenter publication is no longer planned, whichever shall occur first.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
This study was terminated early due to slow accrual and changes to Sponsor's development program priorities. The third dose level (12 µg/kg/day), for Phase 2, was not investigated.
point Of Contact
email
clinicaltrials@menarinistemline.com
organization
Stemline Therapeutics, Inc.
phone
877-332-7967
title
Ira Gupta, MD, Senior Vice President, Clinical Development & Medical Affairs - Hematology

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice